BioMarin Pharmaceutical Inc. (BMRN) Financial Statements
BioMarin Pharmaceutical Inc. (BMRN) reported trailing twelve-month revenue of $3.4B (up 11.2% year on year) and net income of $73.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $738.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 10.8B
- P/E TTM
- 151.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26. Results for the next quarter were released 6 Oct; these figures move once the 10-Q is filed.
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.38 | 0.44 | 0.50 | 0.55 | 0.75 | 0.89 | 1.12 | 1.31 | 1.49 | 1.70 | 1.86 | 1.85 | 2.10 | 2.42 | 2.85 | 3.22 | 3.41 | |
| Gross profit | 0.31 | 0.36 | 0.41 | 0.46 | 0.63 | 0.74 | 0.91 | 1.07 | 1.18 | 1.34 | 1.34 | 1.38 | 1.59 | 1.89 | 2.27 | 2.50 | 2.59 | |
| Research & development | 0.15 | 0.21 | 0.30 | 0.35 | 0.46 | 0.63 | 0.66 | 0.61 | 0.70 | 0.72 | 0.63 | 0.63 | 0.65 | 0.75 | 0.75 | 0.92 | 0.99 | |
| Operating income | 0.00 | -0.03 | -0.11 | -0.16 | -0.09 | -0.11 | -0.80 | -0.01 | -0.12 | -0.10 | -0.04 | -0.08 | 0.16 | 0.19 | 0.48 | 0.41 | 0.15 | |
| Pre-tax income | -0.02 | -0.04 | -0.12 | -0.18 | -0.12 | -0.15 | -0.83 | -0.04 | -0.14 | -0.09 | -0.05 | -0.08 | 0.15 | 0.19 | 0.54 | 0.48 | 0.15 | |
| Income tax | -0.23 | 0.01 | -0.00 | -0.00 | 0.01 | 0.02 | -0.20 | 0.08 | -0.07 | -0.07 | -0.90 | -0.01 | 0.01 | 0.02 | 0.11 | 0.13 | 0.08 | |
| Net income | 0.21 | -0.05 | -0.11 | -0.18 | -0.13 | -0.17 | -0.63 | -0.12 | -0.08 | -0.02 | 0.85 | -0.06 | 0.14 | 0.17 | 0.43 | 0.35 | 0.07 | |
| Diluted EPS ($) | 1.73 | -0.48 | -0.95 | -1.28 | -0.92 | -1.07 | -3.81 | -0.67 | -0.44 | -0.13 | 4.50 | -0.35 | 0.75 | 0.87 | 2.21 | 1.80 | 0.37 | |
| Diluted shares (bn) | 0.126 | 0.112 | 0.120 | — | 0.146 | 0.160 | 0.166 | 0.174 | 0.177 | 0.179 | 0.192 | 0.183 | 0.189 | 0.192 | 0.197 | 0.197 | — |
USD billions · SEC XBRL
BioMarin Pharmaceutical Inc. — questions
- What is BioMarin Pharmaceutical Inc.'s revenue?
- $3.4B over the twelve months to 2026-06-30, up 11.2% year on year, from its 10-Q and 10-K filings.
- What is BioMarin Pharmaceutical Inc.'s net income?
- $73.0M over the twelve months to 2026-06-30.
- What is BioMarin Pharmaceutical Inc.'s free cash flow?
- $738.2M over the twelve months to 2026-06-30.
- What are BioMarin Pharmaceutical Inc.'s diluted earnings per share?
- $0.37 over the twelve months to 2026-06-30.
Every figure on this page comes from BioMarin Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.